Login to Your Account


DEXA cards yet to be shown

A curve ball from the FDA for Repros Therapeutics Inc. played foul with the company's shares as investors learned that U.S. regulators have switched the firm's pre-new drug application meeting from a type B to a less-routine type C session in the first half of next month. more »


Opinion


Partners in Focus